Drug Type Small molecule drug |
Synonyms PBI 05204, PBI-05204, Anvirzel |
Mechanism AP-1 inhibitors(Transcription factor AP1 inhibitors), FGFs inhibitors(Fibroblast growth factors inhibitors), NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H48O9 |
InChIKeyJLPDBLFIVFSOCC-XYXFTTADSA-N |
CAS Registry465-16-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic adenocarcinoma metastatic | Phase 2 | US | 01 Apr 2015 | |
Pancreatic Cancer | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - | |
Neoplasms | Phase 1 | US | 30 Jan 2022 | |
Advanced cancer | Phase 1 | US | 01 Oct 2007 | |
Solid tumor | Phase 1 | US | 01 Oct 2007 | |
COVID-19 | Preclinical | US | - | 06 Nov 2020 |
Glioblastoma | Preclinical | US | 18 Sep 2018 | |
Stroke | Preclinical | US | - |
Phase 2 | 38 | wrmbrrszoc(gniaiwuhfq) = nuasgkjbhp dujetrjibb (zwyzqbotkh ) View more | Positive | 01 Oct 2020 | |||
Phase 2 | - | aybpsxjbrq(evbddiivyr) = hafvrqbjlc abzrpowfjk (knyytidxgh ) View more | Negative | 04 Feb 2020 | |||
Phase 1 | 46 | icdglddsfi(hjxxqemgcn) = hvpmfwpval wqfxdfomcu (rwybtrmbhh ) | - | 20 May 2011 |